Actively Recruiting
Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I
Led by Second Affiliated Hospital of Guangzhou Medical University · Updated on 2024-06-26
60
Participants Needed
1
Research Sites
834 weeks
Total Duration
On this page
Sponsors
S
Second Affiliated Hospital of Guangzhou Medical University
Lead Sponsor
H
Hunan Zhaotai Yongren Medical Innovation Co. Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
T effector cells and NK cells have mutual compensatory killing functions on various of cancer types. For those cancers that have no available targets for CAR-T cell generations, we established potent T cell-like NK cells (ITNK) with a specific conversion protocol for the T cells from the patient, to perform anti-cancer therapy, especially for those cancers that are lack of MHC-I molecule expression. We have finished pre-clinical investigations for the ITNK or CAR-ITNK cell therapy and scheduled to start a clinical phase I study.
CONDITIONS
Official Title
Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with advanced cancer that express low or no MHC-I
- Life expectancy greater than 12 weeks
- Adequate heart, lung, liver, and kidney function
- Availability of autologous T cells for therapy
- Informed consent explained, understood, and signed by patient or guardian
- Patient or guardian has received a copy of the informed consent
You will not qualify if you...
- Previous gene therapy treatment
- Severe viral infections such as hepatitis B, hepatitis C, or HIV
- Known HIV positivity
- History of liver or other organ transplantation
- Active infectious diseases related to bacteria, virus, fungi, or others
- Other severe diseases deemed inappropriate by investigators
- Pregnant or lactating women
- Systemic steroid treatment equivalent to or greater than 0.5 mg prednisone/kg/day
- Other conditions considered inappropriate by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China, 510260
Actively Recruiting
Research Team
Z
Zhenfeng Zhang, MD,PhD
CONTACT
P
Peng Li, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here